食管癌术后应用艾迪注射液对血浆sCD44s影响的临床研究

【作者】 林娜；

【导师】 潘立群；

【作者基本信息】 南京中医药大学 ， 中医外科学， 2005， 硕士

【摘要】 目的 大量研究表明，到目前为止，术后肿瘤的复发转移仍然是肿瘤患者死亡的主要原因，肿瘤的发生发展与机体免疫反应紧密相关。红细胞免疫(RCI)是人体免疫系统的重要组成部分，提高机体红细胞免疫功能能抑制肿瘤的复发转移。 本课题通过检测食管癌患者术后血浆sCD44s，观察食管癌患者术后早期应用艾迪注射液的作用，从分子水平检验其对红细胞免疫功能和肿瘤复发转移的影响，深化课题研究，为围手术期抗肿瘤中药的应用提供理论依据，为开发新一代的抗肿瘤中药制剂奠定临床研究基础。 方法 观察到食管癌患者共9例，实验组4例术后早期应用艾迪注射液，对照组5例术后常规用药，用ELISA方法测定血浆中可溶性CD44s，观察其结果，探讨艾迪注射液提高食管癌患者红细胞免疫功能和抑制肿瘤复发转移的机理。 结果 治疗前(术后1天)血浆sCD44s水平 对照组x±s=249.80±66.71ng／ml，实验组x±s=239.25±72.20ng／ml，经t检验，P=0.41＞0.05，认为两者在统计学上没有显著差异。 治疗后(术后第14天)血浆sCD44s水平 对照组x±s=353.33±60.93ng／ml，实验组x±s=159.67±74.57ng／ml，经t检验，P=0.01＜0.05，认为有显著差异。 结论 两组样本术后1天的血浆sCD44s水平没有显著差异，两组样本来自同一总体。 实验组血浆sCD44s水平下降，对照组血浆sCD44s水平呈上升趋势，两组比较有显著差异。实验组血浆可溶性CD44s水平下降，表明由肿瘤细胞产生的内生蛋白水解酶减少，红细胞膜上结合状态的CD44s表达较多，间接反映红细胞免疫功能提高，肿瘤转移受到抑制，患者预后较好。更多还原

【Abstract】 Objective A great deal research show, for the moment, transfer and recur after operation are still main reasons for tumor sufferer’s death, Occurrence and development of tumor is tied-up closely with system immunoreaction. Red blood cell immunity (RCI) is one important part of immunity, improving RCI function can restrain tumor to transfer.The objective of this research is to study the influence of aidi injection on RCI and tumor transfer in molecule level, by measuring plasma sCD44s, investigating its function on esophageal carcinoma patients after operation early, deepen the research, offer theory proof for apply resist tumor Chinese traditional medicine during all-around operation, to establish clinic study base for explore new generation of resist tumor Chinese traditional medicine.Method We totally got 9 patients, apply early aidi injection after operation on experimental group, control group not yet. Measure plasma sCD44s through ELISA, eualuate aidi injection function on immunity.Result The pre-treatment blood plasma sCD44s level the controlgroup blood plasma sCD44s level is x ± s =249.80 ± 66.71ng/ml, theexperimentation group blood plasma sCD44s level is x ± s =239.25 ± 72.20ng/ml, by t test , P=0.41>0.05, there is no significant difference in statistics between the two groups. After treatment blood plasma sCD44s level the experimentation groupblood plasma sCD44s level is x ± s =159.67 ± 74.57ng/ml, the controlgroup blood plasma sCD44s level is x ± s =353.33 ± 60.93ng/ml, by t test, P=0.01<0.05, there is significant difference in statistics between the two groups.Conclusion The pre-treatment blood plasma sCD44s level of two更多还原